10-Q · May 15, 2026
BioXcel Therapeutics reported significant revenue growth and positive operational metrics in Q1 2026 compared to prior periods, although adjusted EPS showed wider losses than expected. Segment performance remains…
Earnings analysis · 10-Q
BTAI earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
BioXcel reported approximately $0.2 million of second-quarter IGALMI® revenue, roughly flat with $0.206 million in the prior quarter but up from $0.12 million a year earlier; the filing does not provide current-quarter…
Read full summary
BioXcel reported approximately $0.2 million of second-quarter IGALMI® revenue, roughly flat with $0.206 million in the prior quarter but up from $0.12 million a year earlier; the filing does not provide current-quarter EPS, margin or cash-flow figures in the supplied text. The central investment issue is liquidity: the company had $13.8 million of cash, cash equivalents and restricted cash against $107.2 million of debt and acknowledged substantial doubt about its ability to continue as a going concern. The August 21, 2026 lender-acceptable transaction deadline, SEC investigation, TRANQUILITY data-quality concerns and pending regulatory and litigation matters materially outweigh the modest revenue improvement.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Segment
- IGALMI® revenue: approximately $0.2 million for the three months ended June 30, 2026 and $0.4 million for the six months ended June 30, 2026; no reportable segment revenue breakdown was disclosed.
What stood out
-
IGALMI revenue grew year over year
Three-month IGALMI® revenue was approximately $0.2 million, versus $0.206 million in 2026 Q1 and $0.12 million in 2025 Q2, implying roughly flat sequential performance and approximately 67% year-over-year growth based on the reported quarterly history.
-
Commercial strategy remains focused
Management reported $0.4 million of IGALMI® revenue for the six months ended June 30, 2026, while the company continues pursuing a lower-cost hospital/IDN contracting strategy and potential at-home label expansion.
-
Near-term liquidity runway identified
Management said cash, cash equivalents and restricted cash totaled $13.8 million at June 30, 2026 and were expected to fund operations and liquidity requirements through the end of August 2026.
-
At-home sNDA remains under review
The company submitted an IGALMI® supplemental NDA for at-home use on January 14, 2026. The FDA’s PDUFA target action date is November 14, 2026, subject to resolving the requested child-resistant package modification.
-
Disclosure controls remained effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected or were reasonably likely to materially affect controls during the quarter.
What to watch
-
Critical financing and debt deadline
The company reported aggregate principal indebtedness of $107.2 million at June 30, 2026 and stated that it did not have sufficient cash to fund operations and liquidity requirements through the end of August 2026. The Twelfth Amendment requires definitive lender-acceptable transaction agreements by August 21, 2026, creating an acute refinancing or strategic-transaction deadline.
-
Going-concern uncertainty
The filing states that substantial doubt exists regarding going-concern status because cash and liquidity were insufficient to support operations and service debt obligations for at least one year. Stockholders’ deficit was approximately $115.5 million at June 30, 2026, and six-month net loss was $27.4 million.
-
SEC investigation and litigation exposure
The SEC formal investigation, initiated in February 2024, concerns public disclosures about product sales, a Form 483 at a TRANQUILITY II clinical site and securities trading. The company cannot predict whether proceedings will be instituted or their impact on financing efforts.
-
TRANQUILITY development may be delayed
The FDA requested additional information regarding the reliability and consistency of PEC-score measurements in the TRANQUILITY program. FDA feedback indicated that the existing efficacy database included only 70 patients treated with the 60 mcg dose and would require additional efficacy and long-term safety data before an sNDA could be supported.
-
Manufacturing and tariff cost pressure
The company stated that a manufacturing facility of its sole active-pharmaceutical-ingredient supplier is subject to an FDA “official action indicated” status. Separately, a 100% tariff on certain imported patented pharmaceutical products and active ingredients becomes applicable to all other companies on September 29, 2026, potentially increasing manufacturing costs.
-
Ongoing legal proceedings
The preliminary approval of the securities-litigation settlement is not final; the hearing for final approval is scheduled for September 2, 2026. The filing also identifies additional derivative actions and continuing SEC-related proceedings that could create costs and divert management resources.
Management's outlook
No numeric operating guidance was provided. Management stated that cash, cash equivalents and restricted cash of $13.8 million as of June 30, 2026 was expected to fund operations and liquidity requirements through the end of August 2026, but there was no broader revenue or EPS outlook.
Earlier filings 4
10-K · March 27, 2026
The 2025 Form 10-K highlights positive clinical progress for BXCL501 (SERENITY at‑home Phase 3 met its primary objective on August 27, 2025) and an sNDA submitted January 14, 2026 seeking at‑home labeling for IGALMI®,…
10-Q · November 12, 2025
BioXcel reported Q3 product revenue of $98 (in thousands) and GAAP diluted loss per share of $(2.18), missing consensus on both revenue and EPS. The company recorded a quarterly net loss of $30,911 (in thousands),…
10-Q · August 12, 2025
BioXcel reported sharply lower product revenue of $120 thousand in Q2 2025 and a GAAP net loss of $19.187 million (EPS -$2.45). Gross margin collapsed to 10.8% in the quarter versus 94.4% in Q2 2024, while operating…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.